Interview with Engage Therapeutics’ founder Greg Mayes appears in Epilepsy Foundation’s June 2019 Research Quarterly

Engage Therapeutics sponsors Kurt Eichenwald’s Miami appearance to discuss “A Mind Unravled,” a chronicle of his life with epilepsy.
July 1, 2019
Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia
July 9, 2019

Greg discusses his personal connection to epilepsy and the challenges his company faces in finding the perfect study participants for the clinical trial of Staccato Alprazolam, and why the work Engage Therapeutics is engaged in is so important.

Click here to read the interview with Greg Mayes (PDF)

Click here for the full Epilepsy Foundation’s June 2019 Research Quarterly report (PDF)